1 Jo VY,Doyle LA.Refinements in sarcoma classification in the current 2013 World Health Organization classification of tumours of soft tissue and bone[J].Surg Oncol Clin N Am,2016,25(4):621-643. 2 Tan MTL,Thompson SR,Schipp D,et al.Patterns of care of superficial soft tissue sarcomas:it is not always just a lump[J].Asia Pac J Clin Oncol,2018[Epub ahead of print]. 3 Bandino A,Compagnone A,Bravoco V,et al.β-catenin triggers nuclear factor κB-dependent up-regulation of hepatocyte inducible nitric oxide synthase[J].Int J Biochem Cell B,2008,40(9):1861-1871. 4 Martinez-Font E,Felipe-Abrio I,Calabuig-Fariñas S,et al.Disruption of TCF/β-catenin binding impairs Wnt signalling and induces apoptosis in soft tissue sarcoma cells[J].Mol Cancer Ther,2017,16(6):1166-1176. 5 王翠翠,张薇,刘春霞,等.滑膜肉瘤中E-、N-cadherin和β-catenin的表达及意义[J].临床与实验病理学杂志,2012,28(8):874-879. 6 Indersie E,Lesjean S,Hooks KB,et al.MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting β-catenin and Wnt signaling[J].Hepatol Commun,2017,1(2):168-183. 7 Ng TL,Gown AM,Barry TS,et al.Nuclear beta-catenin in mesenchymal tumors[J].Mod Pathol,2005,18(1):68-74. 8 Saito T,Oda Y,Sakamoto A,et al.Prognostic value of the preserved expression of the E-cadherin and catenin families of adhesion molecules and of beta-catenin mutations in synovial sarcoma[J].J Pathol,2000,192(3):342-350. 9 Bouron-Dal Soglio D,Rougemont AL,Absi R,et al.Beta-catenin mutation does not seem to have an effect on the tumorigenesis of pediatric rhabdomyosarcomas[J].Pediatr Dev Pathol,2009,12(5):371-373. 10 Aggarwal A,Prinz-Wohlgenannt M,Grñschel C,et al.The calcium-sensing receptor suppresses epithelial-to-mesenchymal transition and stem cell-like phenotype in the colon[J]Mol Cancer,2015,14:61. 11 Zheng L,Liu Y,Pan J.Inhibitory effect of pyrvinium pamoate on uveal melanoma cells involves blocking of Wnt/β-catenin pathway[J].Acta Biochim Biophys Sin(Shanghai),2017,49(10):890-898. 12 Annavarapu SR,Cialfi S,Dominici C,et al.Characterization of Wnt/β-catenin signaling in rhabdomyosarcoma[J].Lab Invest,2013,93(10):1090-1099. 13 Cowan ML,Thompson LD,Leon ME,et al.Low-grade fibromyxoid sarcoma of the head and neck:a clinicopathologic series and review of the literature[J].Head Neck Pathol,2016,10(2):161-166. 14 Rooper LM,Huang SC,Antonescu CR,et al.Biphenotypic sinonasal sarcoma:an expanded immunoprofile including consistent nuclear β-catenin positivity and absence of SOX10 expression[J].Hum Pathol,2016,55:44-50. 15 Qi Y,Wang CC,He YL,et al.The correlation between morphology and the expression of TGF-β signaling pathway proteins and epithelial-mesenchymal transition-related proteins in synovial sarcomas[J].Int J Clin Exp Pathol,2013,6(12):2787-2799. 16 Yang J,Du X,Wang G,et al.Mesenchymal to epithelial transition in sarcomas[J].Eur J Cancer,2014,50(3):593-601. 17 Zhang P,Bill K,Liu J,et al.MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling[J].Cancer Res,2012,72(7):1751-1762. 18 Sakamoto A,Oda Y,Adachi T,et al.β-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma.[J].Arch Pathol Lab Med,2002,126(9):1071-1078. 19 Gogou P,Pakos E,Batistatou A,et al.Clinicopathologic study of E-cadherin/beta-catenin complex,and topoisomerase-II in a series of 71 liposarcoma cases.[J].World J Surg Oncol,2012,10:28. 20 Weiss S,Goldglum J.Enzinger and Weiss's soft tissue tumors[M].4th ed.Philadelphia:Mosby,2001. 21 Honoki K,Fujii H,Tohma Y,et al.Comparison of gene expression profiling in sarcomas and mesenchymal stem cells identifies tumorigenic pathways in chemically induced rat sarcoma model.[J].ISRN Oncol,2012,2012:909453. 22 Kouvidi K,Berdiaki A,Tzardi M,et al.Receptor for hyaluronic acid-mediated motility(RHAMM)regulates HT1080 fibrosarcoma cell proliferation via a β-catenin/c-myc signaling axis[J].Biochim Biophys Acta,2016,1860(4):814-824. 23 Barrott JJ,Illum BE,Jin H,et al.β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition[J].Oncotarget,2015,6(26):22758-22766. 24 Tang J,Shi H,Li H,et al.The interaction of hepatoma-derived growth factor and β-catenin promotes tumorigenesis of synovial sarcoma[J].Tumour Biol,2016,37(8):10287-10301. 25 Pedersen EA,Menon R,Bailey KM,et al.Activation of Wnt/β-catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states[J].Cancer Res,2016,76(17):5040-5053. 26 Hawkins AG,Basrur V,da Veiga Leprevost F,et al.The Ewing sarcoma secretome and its response to activation of Wnt/beta-catenin signaling[J].Mol Cell Proteomics,2018,17(5):901-912. 27 Singh S,Vinson C,Gurley CM,et al.Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice[J].Am J Pathol,2010,177(4):2055-2066. 28 Trautmann M,Sievers E,Aretz S,et al.SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma[J].Oncogene,2014,33(42):5006-5016. 29 Dräger J,Simon-Keller K,Pukrop T,et al.LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma[J].Oncotarget,2017,8(2):3259-3273. 30 Chen EY,DeRan MT,Ignatius MS,et al.Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma[J].Proc Natl Acad Sci U S A,2014,111(14):5349-5354. 31 Kephart JJ,Tiller RG,Crose LE,et al.Secreted frizzled-related protein 3(SFRP3)is required for tumorigenesis of PAX3-FOXO1-positive alveolar rhabdomyosarcoma[J].Clin Cancer Res,2015,21(21):4868-4880. 32 Villar VH,Vögler O,Barceló F,et al.Down-regulation of AKT signalling by ursolic acid induces intrinsic apoptosis and sensitization to doxorubicin in soft tissue sarcoma.[J].PLoS One,2016,11(5):e0155946. 33 Cironi L,Petricevic T,Fernandes Vieira V,et al.The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma[J].Sci Rep,2016,6:22113. 34 Barham W,Frump AL,Sherrill TP,et al.Targeting the wnt pathway in synovial sarcoma models[J].Cancer Discov,2013,3(11):1286-1301. |